{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:08:37Z","timestamp":1753891717751,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation. We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery. Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one). Single doses of zolpidem ranged between 2.5 and 10 mg, while daily dosages ranged from 10 to 30 mg. The zolpidem dose prescribed was 5\u201310 mg, with single and daily doses of 7 \u00b1 2.9 and 14.5 \u00b1 6.0 mg, respectively. With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.1 \u00b1 6.7 to 3.7 \u00b1 2.5 (50.6% improvement, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001). Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively. No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale. Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2\u20133 h. Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively. Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited.<\/jats:p>","DOI":"10.3389\/fneur.2022.837023","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T06:44:30Z","timestamp":1651560270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Shiro","family":"Horisawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ebise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nishitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takakazu","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaomi","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","article-title":"Treatment of dystonia","volume":"5","author":"Jankovic","year":"2006","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1468-1331.2004.00845.x","article-title":"Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options","volume":"11","author":"Balash","year":"2004","journal-title":"Eur J Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1468-1331.2010.03059.x","article-title":"Surgical treatment of dystonia","volume":"17","author":"Krauss","year":"2010","journal-title":"Eur J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1212\/WNL.58.4.662","article-title":"Zolpidem improves dystonia in \u201cLubag\u201d or X-linked dystonia-parkinsonism syndrome","volume":"58","author":"Evidente","year":"2002","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/mds.20085","article-title":"Improvement of blepharospasm with zolpidem","volume":"19","author":"Garretto","year":"2004","journal-title":"Mov Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1179\/crn.2004.041","article-title":"Treatment of inferior lateral pterygoid muscle dystonia with zolpidem tartrate, botulinum toxin injections, and physical self-regulation procedures: a case report","volume":"22","author":"Vazquez-Delgado","year":"2004","journal-title":"Cranio."},{"key":"B7","first-page":"22","article-title":"Treatment of post-traumatic segmental axial dystonia with zolpidem","volume":"156","author":"Seo","year":"2007","journal-title":"Mov Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/mds.22179","article-title":"Successful treatment of the Meige syndrome with oral zolpidem monotherapy","volume":"23","author":"An","year":"2008","journal-title":"Mov Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/mds.22745","article-title":"Excellent response to oral zolpidem in a sporadic case of the myoclonus dystonia syndrome","volume":"24","author":"Park","year":"2009","journal-title":"Mov Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fneur.2012.00058","article-title":"Efficacy of zolpidem for dystonia: a study among different subtypes","volume":"3","author":"Miyazaki","year":"2012","journal-title":"Front Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.parkreldis.2014.11.006","article-title":"Response to zolpidem in oromandibular dystonia: a case report","volume":"21","author":"Martinez-Ramirez","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/mdc3.12280","article-title":"Treatment of isolated dystonia with zolpidem","volume":"3","author":"Miyazaki","year":"2016","journal-title":"Mov Disord Clin Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3389\/fneur.2019.00779","article-title":"Zolpidem for the treatment of dystonia","volume":"10","author":"Badillo","year":"2019","journal-title":"Front Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3171\/spi.2002.97.2.0201","article-title":"A new denervation procedure for idiopathic cervical dystonia","volume":"97","author":"Taira","year":"2002","journal-title":"J Neurosurg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.23877","article-title":"Long-term improvement of musician's dystonia after stereotactic ventro-oral thalamotomy","volume":"74","author":"Horisawa","year":"2013","journal-title":"Ann Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/mds.26726","article-title":"Gamma knife Ventro-oral thalamotomy for musician's dystonia","volume":"32","author":"Horisawa","year":"2017","journal-title":"Mov Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3171\/2017.7.JNS17323","article-title":"Long-term outcome of pallidal stimulation for Meige syndrome","volume":"130","author":"Horisawa","year":"2018","journal-title":"J Neurosurg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2019.9.JNS191202","article-title":"Unilateral pallidotomy in the treatment of cervical dystonia: a retrospective observational study","volume":"1","author":"Horisawa","year":"2019","journal-title":"J Neurosurg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acn3.51333","article-title":"Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia","volume":"8","author":"Horisawa","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/mds.25552","article-title":"Medical treatment of dystonia","volume":"28","author":"Jankovic","year":"2013","journal-title":"Mov Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp.63.5.642","article-title":"Symptomatic and functional outcome of surgical treatment of cervical dystonia","volume":"63","author":"Krauss","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1056\/NEJMoa063618","article-title":"Pallidal deep-brain stimulation in primary generalized or segmental dystonia","volume":"355","author":"Kupsch","year":"2006","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S1474-4422(14)70143-7","article-title":"Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial","volume":"13","author":"Volkmann","year":"2014","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1523\/JNEUROSCI.12-03-01040.1992","article-title":"The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon","volume":"12","author":"Wisden","year":"1992","journal-title":"J Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00213-008-1431-1","article-title":"A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T","volume":"203","author":"Licata","year":"2009","journal-title":"Psychopharmacology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1471-4159.1987.tb00977.x","article-title":"Autoradiographic localization of [3H] zolpidem binding sites in the rat CNS: comparison with the distribution of [3H] flunitrazepam binding sites","volume":"49","author":"Niddam","year":"1987","journal-title":"J Neurochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2020.06.016","article-title":"Medical management of myoclonus-dystonia and implications for underlying pathophysiology","volume":"77","author":"Fearon","year":"2020","journal-title":"Parkinsonism Relat Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S0140-6736(05)62416-6","article-title":"Zolpidem in Parkinson's disease","volume":"349","author":"Daniele","year":"1997","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jocn.2007.07.082","article-title":"Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinson's disease","volume":"15","author":"Chen","year":"2008","journal-title":"J Clin Neurosci."},{"key":"B30","first-page":"84","article-title":"Zolpidem improves neuropsychiatric symptoms and motor dysfunction in a patient with Parkinson's disease after deep brain stimulation","volume":"21","author":"Huang","year":"2012","journal-title":"Acta Neurol Taiwan."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnsys.2014.00033","article-title":"Disrupting neuronal transmission: mechanism of DBS?","volume":"8","author":"Chiken","year":"2014","journal-title":"Front Syst Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.837023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T06:44:36Z","timestamp":1651560276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.837023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":32,"alternative-id":["10.3389\/fneur.2022.837023"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.837023","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"article-number":"837023"}}